Skip to main content

FENNEC PHARMACEUTICALS INC

For the period ended Mar 31, 2024. Filed May 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

FENC$10.83+10.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 6. Exhibits

ExhibitNo.Description
​​​
10.11​License and Supply Agreement, dated March 15, 2024, between Fennec Pharmaceuticals, Inc. and Norgine Pharma UK Limited.
​​​
31.1​Certification of Chief Executive Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
​
31.2​Certification of Chief Financial Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
​
32.1​Certification of Chief Executive Officer and Chief Financial Officer of the Company in accordance with Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).
​
99.1​Press Release for Quarter Ended March 31, 2024 (filed herewith).
​
101.INS*​Inline XBRL Instance Document
​​​
101.SCH*​Inline XBRL Taxonomy Extension Schema Document
​​​
101.CAL*​Inline XBRL Taxonomy Extension Calculation Linkbase Document
​​​
101.DEF*​Inline XBRL Taxonomy Extension Definition Linkbase Document
​​​
101.LAB*​Inline XBRL Taxonomy Extension Label Linkbase Document
​​​
101.PRE*​Inline XBRL Taxonomy Extension Presentation Linkbase Document
​​​
104​Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)
  1. In accordance with Item 601(b)(10)(iv) of Regulation S-K, certain provisions and terms of this exhibit have been redacted. Fennec will provide an unredacted copy of the exhibit on a supplemental basis to the SEC or its staff upon request.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.